** Shares of eye-drug maker Harrow Inc HROW.O fall 24.7% to $39 premarket
** Co's Q3 revenue rose 43.8% to $49.3 mln, missing estimates of $52.8 mln as per data compiled by LSEG
** HROW's adj. earnings before interest, tax, depreciation and amortization at $8.8 mln vs estimates of $11.7 mln
** Reported qtrly. loss of 12 cents per share
** Alongside 44% Y‑o‑Y revenue growth, co achieved a modest sequential revenue increase, despite Q3's traditional summer seasonality and operational bumps that pushed some Q3 revenue into Q4 - Mark L. Baum, CEO
** Avg rating of 4 brokerages is a "buy"; median PT is $60 - LSEG data
** As of last close, stock has more than quadrupled YTD
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.